TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33334157

Group type: COMPARATOR
Intervention: Pathway 1 (usual care): Community health workers (CHWs) and primary care providers (PCPs) refer patients to district-level mental health clinics.
Number of subjects: 4700000

Group type: EXPERIMENTAL
Intervention: Pathway 2 (screen, refer, and treat): CHWs screen and refer patients to PCPs for behavioral and pharmacological EBIs in community clinics.
Number of subjects: 4700000

Group type: EXPERIMENTAL
Intervention: Pathway 3 (community mental health stepped care): CHWs screen patients and deliver behavioral EBIs in the community and refer medication management cases to PCPs in clinics.
Number of subjects: 4700000
Study: 35585519

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking on mother’s finger (A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pacifier (B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 150
Study: 33675081

Group type: EXPERIMENTAL
Intervention: Whey protein (70 g/280 kcal) drink
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (water with diet cordial, 2 kcal) drink
Number of subjects: 32
Study: 35148800

Group type: EXPERIMENTAL
Intervention: Community intervention for tuberculosis household child contact management
Number of subjects: 0
Study: 34959840

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) for 8 weeks
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance period (12 weeks)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance period
Number of subjects: 162
Study: 34436927

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 349
Study: 32691102

Group type: EXPERIMENTAL
Intervention: Municipal solid waste compost (MSWC) at 40 t ha−1 year−1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Municipal solid waste compost (MSWC) at 80 t ha−1 year−1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Municipal solid waste compost (MSWC) at 120 t ha−1 year−1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Farmyard manure (FM) at 40 t ha−1 year−1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Farmyard manure (FM) at 120 t ha−1 year−1
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (unamended soil)
Number of subjects: 4
Study: 36760537

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (ESWT) applied once a week for 5 weeks, combined with a 5-week advanced rehabilitation training program (30 minutes/session, 5 times/week) starting at 3 months postoperatively
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group followed a 5-week advanced rehabilitation training program (30 minutes/session, 5 times/week) starting at 3 months postoperatively
Number of subjects: 30
Study: 33196155

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted, target INR 2.0 to 3.0)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1005
Study: 35781888

Group type: EXPERIMENTAL
Intervention: 3-day antibiotic protocol (500 mg amoxicillin and metronidazole 3 times a day for 3 days, followed by placebo for 4 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 7-day antibiotic protocol (500 mg amoxicillin and metronidazole 3 times a day for 7 days)
Number of subjects: 50
Study: 34112605

Group type: EXPERIMENTAL
Intervention: 7-week meditation and mindfulness programme with standard supportive care
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard supportive care only
Number of subjects: 76
Study: 35485332

Group type: EXPERIMENTAL
Intervention: JNJ-64794964 0.2 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: JNJ-64794964 0.6 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: JNJ-64794964 1.25 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: JNJ-64794964 1.8 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: JNJ-64794964 1.25 mg (MD phase)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (SAD phase)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (MD phase)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: JNJ-64794964
Number of subjects: 34
Study: 35810356

Group type: EXPERIMENTAL
Intervention: rh‐bFGF nasal‐spray
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: rh‐bFGF nasal‐drops
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: rh‐bFGF nasal‐spray and drop
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 34371914

Group type: EXPERIMENTAL
Intervention: Tailored feedback (graph and prompt showing the proportion of ‘everyday’ foods selected)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Standard online ordering system
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Both groups (Tailored feedback and Standard online ordering)
Number of subjects: 2200
Study: 32727540

Group type: EXPERIMENTAL
Intervention: Persian version of the Celiac Disease Adherence Test (Pv‐CDAT)
Number of subjects: 230
Study: 36335297

Group type: EXPERIMENTAL
Intervention: 100-μg dexmedetomidine plus 35-mL 0.5% levobupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50-μg dexmedetomidine plus 35-mL 0.5% levobupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 35-mL 0.5% levobupivacaine plus normal saline
Number of subjects: 60
Study: 33908301

Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 36049407

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over right dorsolateral prefrontal cortex for 10 consecutive days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 25
Study: 36192785

Group type: COMPARATOR
Intervention: REP (Replicating Effective Programs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enhanced REP (with 9 months of external facilitation)
Number of subjects: 32
Study: 33065664

Group type: EXPERIMENTAL
Intervention: Intramedullary nail
Number of subjects: 12

Group type: COMPARATOR
Intervention: Locking plate and lag screw fixation
Number of subjects: 12
Study: 33991221

Group type: EXPERIMENTAL
Intervention: Intravaginal estriol 0.03 mg plus Lactobacillus acidophilus 100 million viable cell vaginal tablets
Number of subjects: 78

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 78
Study: 32390563

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 35286921

Group type: EXPERIMENTAL
Intervention: Suspected fetal growth restriction (FGR)
Number of subjects: 1902
Study: 32668323

Group type: EXPERIMENTAL
Intervention: LUS-guided treatment
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 33501671

Group type: EXPERIMENTAL
Intervention: Nusinersen (12‐mg scaled equivalent dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 21

Group type: COMPARATOR
Intervention: Transitioned from sham to nusinersen
Number of subjects: 21
Study: 33113900

Group type: EXPERIMENTAL
Intervention: Supervisors' workaholism
Number of subjects: 0
Study: 34489756

Group type: EXPERIMENTAL
Intervention: LIFEwithIBD intervention + Treatment As Usual (TAU)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 61
Study: 32266682

Group type: EXPERIMENTAL
Intervention: Canine assisted occupational therapy (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Occupational therapy sessions as usual (waitlist control group, n=11)
Number of subjects: 22
Study: 35483209

Group type: EXPERIMENTAL
Intervention: ALIMFUS therapy for 10 minutes on alternate days for 90 days
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: ALIMFUS therapy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 34678762

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 35922010

Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Closed Treatment (CT)
Number of subjects: 116
Study: 32992206

Group type: EXPERIMENTAL
Intervention: Interactive group session focused on stroke education
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 199
Study: 35381064

Group type: EXPERIMENTAL
Intervention: Cisplatin at optimal dose of 160 mg/m2 during concurrent phase
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Cisplatin at optimal dose of 260 mg/m2 during induction/adjuvant phase
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Cisplatin throughout treatment (no replacement by carboplatin)
Number of subjects: 742
Study: 34311679

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 116
Study: 32552805

Group type: EXPERIMENTAL
Intervention: Peyton's '4-step Approach' (n=45)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Halsted's 'See One, Do One' (n=57)
Number of subjects: 102
Study: 35105640

Group type: EXPERIMENTAL
Intervention: WeChat applet+step goal setting+gamification
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: WeChat applet+step goal setting+gamification+collaboration
Number of subjects: 108

Group type: COMPARATOR
Intervention: WeChat applet+step goal setting
Number of subjects: 108
Study: 32833698

Group type: EXPERIMENTAL
Intervention: Vancomycin powder
Number of subjects: 175

Group type: COMPARATOR
Intervention: No vancomycin powder
Number of subjects: 175
Study: 35641012

Group type: EXPERIMENTAL
Intervention: Behaviour change physiotherapy intervention (6, 30 min weekly group-based exercise sessions preceded by a 30 min cognitive behaviour discussion group)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual care (6, 30 min weekly group-based exercise sessions)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Behaviour change physiotherapy intervention
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study: 33093457

Group type: EXPERIMENTAL
Intervention: IRE plus allogeneic γδ T-cell infusion (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: IRE plus allogeneic γδ T-cell infusion (multiple courses)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: IRE plus allogeneic γδ T-cell infusion (single course)
Number of subjects: 62

Group type: COMPARATOR
Intervention: IRE alone (Group B)
Number of subjects: 62
Study: 33297719

Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate (UPA) 5 mg/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 35222686

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pathological examination
Number of subjects: 72
Study: 32583431

Group type: EXPERIMENTAL
Intervention: Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Number of subjects: 91
Study: 34146100

Group type: EXPERIMENTAL
Intervention: RSVPreF3 vaccine (30/60/120 µg)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 34435472

Group type: COMPARATOR
Intervention: PP0 (0 pmol*kg‐1 *min‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PP3 (3 pmol*kg‐1 *min‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PP10 (10 pmol*kg‐1 *min‐1)
Number of subjects: 12
Study: 33239409

Group type: EXPERIMENTAL
Intervention: Esaxerenone (1.25 mg/d titrated to 2.5 mg/d)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 36075311

Group type: EXPERIMENTAL
Intervention: Socially-oriented negative affect induction
Number of subjects: 116

Group type: COMPARATOR
Intervention: Neutral affect induction
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: All participants (regardless of condition)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: High sugar beverage consumption
Number of subjects: 116
Study: 32436638

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14443
Study: 36322536

Group type: EXPERIMENTAL
Intervention: Indoor environment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simulated outdoor environment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Outdoor environment
Number of subjects: 48
Study: 34371803

Group type: EXPERIMENTAL
Intervention: 10,000 IU/day for 8 weeks followed by 1000 IU/day for 4 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 50,000 IU/week for 12 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 100,000 IU every other week for 12 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study: 32521250

Group type: EXPERIMENTAL
Intervention: TS-121 10 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TS-121 50 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 35708559

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 32014520

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 800 mcg buccally
Number of subjects: 719
Study: 33203692

Group type: EXPERIMENTAL
Intervention: Cetuximab plus 5-fluorouracil and oxaliplatin
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Genetic variants in the retinoic acid receptor alpha (RARA) gene
Number of subjects: 1209
Study: 32086878

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 33687734

Group type: EXPERIMENTAL
Intervention: Tongue cleaning with routine oral care
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine oral care alone (Control)
Number of subjects: 24
Study: 33118727

Group type: EXPERIMENTAL
Intervention: Bretschneider's HTK solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 50
Study: 36148735

Group type: EXPERIMENTAL
Intervention: Two-thumbs encircling hand technique (TTHT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Two-fingers technique (TFT)
Number of subjects: 33
Study: 32527261

Group type: EXPERIMENTAL
Intervention: PopART standard of care door‐to‐door HTS plus oral HIVST (33 clusters)
Number of subjects: 66

Group type: COMPARATOR
Intervention: PopART standard of care door‐to‐door HTS (33 clusters)
Number of subjects: 66
Study: 36764948

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Compomer
Number of subjects: 120
Study: 33215948

Group type: EXPERIMENTAL
Intervention: Mirror Effect Plus Protocol (MEPP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard medication for acute BP
Number of subjects: 20
Study: 33768697

Group type: EXPERIMENTAL
Intervention: Omental roll-up
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-omental roll-up
Number of subjects: 68
Study: 33523087

Group type: EXPERIMENTAL
Intervention: Atraumatic anesthesia without a needle (Comfort‐in®)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional anesthesia by blocking the posterior superior alveolar nerve (PSAN) and Greater Palatine Nerve (GPN)
Number of subjects: 14
Study: 34231852

Group type: EXPERIMENTAL
Intervention: POCER index based on ulcer depth and circumference at the anastomosis at 6 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: POCER index at 6 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Rutgeerts score at 6 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: POCER index of ≥2
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Rutgeerts score of ≥i2
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: POCER index
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Spearman's correlation of POCER index with Rutgeerts score
Number of subjects: 85
Study: 34190882

Group type: EXPERIMENTAL
Intervention: FOCUS-PDCA procedure
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine nursing intervention (Control)
Number of subjects: 160
Study: 33662594

Group type: EXPERIMENTAL
Intervention: Mailed outreach strategy to promote HCC surveillance
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Regularized logistic regression (RLR) model
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Gradient boosting machine (GBM) model
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Predictive models
Number of subjects: 1200
Study: 33509056

Group type: EXPERIMENTAL
Intervention: Breath awareness training
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Loving-kindness training
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Gratitude training
Number of subjects: 162

Group type: COMPARATOR
Intervention: Attentional control
Number of subjects: 162
Study: 34212120

Group type: EXPERIMENTAL
Intervention: Qualitative focus groups and interviews with parents, former patients, and clinicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial design incorporating parent and former patient perspectives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-sided leaflet providing information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addressing clinician biases
Number of subjects: 0
Study: 33127947

Group type: EXPERIMENTAL
Intervention: L. reuteri oil drops and ω‐3 PUFA capsules
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: L. reuteri and placebo regarding ω‐3 PUFA
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo capsules and placebo oil drops
Number of subjects: 88
Study: 616805373

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33714862

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 116
Study: 32268971

Group type: EXPERIMENTAL
Intervention: CACFP sites
Number of subjects: 680

Group type: COMPARATOR
Intervention: Non-CACFP sites
Number of subjects: 680
Study: 34455801

Group type: EXPERIMENTAL
Intervention: Mechanical inoculation with peanut leaf sap containing TuMV; confirmed by RT-PCR and western blot assay.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Mock-inoculated plants (control group).
Number of subjects: 6
Study: 32451010

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) applied for six days per trial, total of 2 trials
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 42
Study: 36475283

Group type: EXPERIMENTAL
Intervention: Novel information booklet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Currently available written OA resource
Number of subjects: 64
Study: 34438047

Group type: COMPARATOR
Intervention: Heart-rate variability biofeedback (BFB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Combined treatment (BFB + TDCS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Left dlPFC anodal tDCS (TDCS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral video viewing (CTRL)
Number of subjects: 80
Study: 35429046

Group type: EXPERIMENTAL
Intervention: Expert-match treatment
Number of subjects: 402

Group type: COMPARATOR
Intervention: Self-matching treatment
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: High neuroticism score
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: High neuroticism, openness, extraversion; low conscientiousness
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Low conscientiousness
Number of subjects: 402
Study: 32730977

Group type: EXPERIMENTAL
Intervention: Bumetanide (1.0 mg twice daily for 91 days)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 92
Study: 32236116

Group type: EXPERIMENTAL
Intervention: Post-meal walking for 15-20 minutes after one meal a day for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: One prandial insulin injection before breakfast or main meal with rapid-acting insulin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Post-meal walking
Number of subjects: 14

Group type: COMPARATOR
Intervention: One prandial insulin injection
Number of subjects: 14
Study: 616121059

Group type: EXPERIMENTAL
Intervention: Drop A (propylene glycol and glycerin containing drop)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Drop B (carbomer containing drop)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline eye drop (Ocufresh eye wash)
Number of subjects: 15
Study: 36027558

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 543
Study: 33951360

Group type: EXPERIMENTAL
Intervention: Rifapentine with moxifloxacin
Number of subjects: 2516

Group type: COMPARATOR
Intervention: Control (6-month regimen with rifampin, isoniazid, pyrazinamide, and ethambutol)
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: Rifapentine without moxifloxacin
Number of subjects: 2516
Study: 35299013

Group type: EXPERIMENTAL
Intervention: 360-degree VR-video
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (standard information leaflet)
Number of subjects: 83
Study: 33373445

Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis (DF)
Number of subjects: 39
Study: 34024658

Group type: EXPERIMENTAL
Intervention: PCV10 (n=55)
Number of subjects: 101

Group type: COMPARATOR
Intervention: PCV13 (n=46)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 101

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 101
Study: 36494726

Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging (HSI) group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 34831691

Group type: EXPERIMENTAL
Intervention: Almond protein powder
Number of subjects: 20

Group type: COMPARATOR
Intervention: Whey protein powder
Number of subjects: 20